SPARC grants license to Tripoint Therapeutics to commercialize Elepzia XR
Under terms of the license agreement, SPARC will be eligible to receive tiered royalties ranging from 15% to 50% on net sales. Tripoint will be responsible for all US regulatory submissions and payment of annual PDUFA fees for Elepsia™ XR 1000 mg and Elepsia™ XR 1500 mg.
The initial term of the agreement shall be 5 years and may be further extended as per mutual agreement between the parties.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content